The (u)ltrasound-based (W)ashington (M)olecular (I)maging and (T)herapy center, or uWAMIT, focuses on the discovery, development, translation, and commercialization of molecular imaging and therapy technologies.
At uWAMIT we believe molecular imaging and therapy will shape the future of medicine enabling personalized diagnosis and treatment of diseases. Currently, healthcare spending represents more than 15% of the United States Gross Domestic Product and is growing rapidly. The traditional approach to treating disease is reactive – we wait until someone is sick before treating the disease with expensive procedures. We believe that a radical departure from this traditional approach is required to contain healthcare costs. Some predict that shifting to predictive, preventative healthcare delivery will save over $250B in healthcare spending.
At uWAMIT we believe the key to cost containment is to shift from diagnosing symptomatic patients to detecting disease in a presymptomatic population, ie. to shift to personalized healthcare delivery. To do this, uWAMIT focuses it’s research on molecular imaging and therapy technologies. Molecular imaging and therapy enables personalized healthcare delivery in the following way:
1) Molecular screening identifies a high risk individual
2) Molecular imaging tests confirm disease onset and location specific to individual
3) Targeted molecular therapies specific to the individual are delivered to treat disease
At uWAMIT we believe ultrasound will be one of the major enablers of molecular imaging and therapy. Just as in conventional imaging where more ultrasound procedures are performed than any other modality, ultrasound will become a primary delivery mechanism for molecular medicine. Ultrasound is widely available, has low operating and capital costs, and operates in real time in the clinic.
uWAMIT is focused on the discovery, development, translation, and commercialization of molecular imaging and therapy technology. uWAMIT is strategically focused on bridging the so called “Valley of Death”- where good ideas by university investigators are lost from evolving into real commercial solutions for improved Healthcare. uWAMIT bridges this gap by focusing on the clinical outcomes and specific clinical constraints that develop into healthcare opportunities. uWAMIT aligns the clinical market opportunity with internal research objectives to connect opportunity with innovation. uWAMIT is strategically positioned to develop new companies and partner with existing companies to pursue market opportunities in molecular imaging and therapy.
uWAMIT is strategically positioned to:
1) Focus on clinical outcomes and specific clinical constraints that develop into healthcare opportunities.
2) Align clinical market opportunities with internal research objectives connecting opportunity with innovation.
3) Develop new companies and license existing technology.
4) Partner with existing companies to pursue market opportunities.